- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about CMNDF
Recent news which mentions CMNDF
This Psychedelics Company Begins Trading On NASDAQ With $7.5M Offering Then Reverse Stock Split
November 15, 2022
From Benzinga
Psychedelics Biotechs Clearmind And Mydecine Share Consolidation And Subscription Agreements
September 26, 2022
From Benzinga
SciSparc And Clearmind Partnership Yields 3rd Patent Application For The Treating Of Obesity And Metabolic Syndromes
September 22, 2022
From Benzinga
Additional Positive Results Revealed In Cocaine Addiction Treatment Through SciSparc-Clearmind Collaboration
August 25, 2022
From Benzinga
From Benzinga
Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know
August 24, 2022
From Benzinga
From Benzinga
From Benzinga
SciSparc Ltd. Announces Initial Positive Results For The Cocaine Addiction Treatment Of Clearmind Medicine Inc.
June 07, 2022
From Benzinga
SciSparc & Clearmind Medicine Team Up On Patent For Psychedelic Combination To Treat Cocaine Addiction
June 02, 2022
From Benzinga
From Benzinga
New Psychedelic-Based Alcohol Substitute Approved In India, Produced By Clearmind Medicine
June 01, 2022
From Benzinga
High Hopes For Alcohol Use Disorder Treatment: Clearmind's Successful Pre-IND Meeting With The FDA
May 26, 2022
Tickers
CMNDF
From Benzinga
From Benzinga
Psychedelic Treatment For Alcoholism? Clearmind Medicine And SciSparc Collaboration Yields Positive Results
May 24, 2022
From Benzinga
Clearmind: Positive Preclinical Evidence For Flagship Psychedelic Molecule, Looks To Human Trials Before Year End
May 19, 2022
Tickers
CMNDF
From Benzinga
From Benzinga
Has Clearmind Developed A Psychedelics-Based Drug That Can Treat Alcoholism? The FDA Is Interested
May 13, 2022
From Benzinga
From Benzinga
From Benzinga
Alcoholism & Psychedelics: Clearmind Trials Reveal Certain Psychedelics Help Reduce Alcohol Consumption In Mice
March 17, 2022
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.